
Multifactorial Design of a Supramolecular Peptide Anti-IL-17 Vaccine Towards the Therapy of Psoriasis
Present therapies for power immune-mediated ailments corresponding to psoriasis, rheumatoid arthritis, or Crohn’s illness generally depend on cytokine neutralization utilizing monoclonal antibodies; nevertheless, such approaches have drawbacks.
Frequent repeated dosing can result in the formation of anti-drug antibodies and affected person compliance points, and it’s troublesome to establish a single antibody that’s broadly efficacious throughout numerous affected person populations. As an alternative choice to monoclonal antibody remedy, anti-cytokine immunization is a possible means for long-term therapeutic management of power inflammatory ailments.
Right here we report a supramolecular peptide-based method for elevating antibodies in opposition to IL-17 and reveal its efficacy in a murine mannequin of psoriasis. B-cell epitopes from IL-17 had been co-assembled with the common T-cell epitope PADRE utilizing the Q11 self-assembling peptide nanofiber system. These supplies, with or with out adjuvants, raised antibody responses in opposition to IL-17. Exploiting the modularity of the system, multifactorial experimental designs had been used to pick out formulations maximizing titer and avidity.
In a mouse mannequin of psoriasis induced by imiquimod, unadjuvanted nanofibers had therapeutic efficacy, which may very well be enhanced with alum adjuvant however reversed with CpG adjuvant. Measurements of antibody subclass induced by adjuvanted and unadjuvanted formulations revealed sturdy correlations between therapeutic efficacy and titers of IgG1 (improved efficacy) or IgG2b (worsened efficacy).
These findings have necessary implications for the event of anti-cytokine energetic immunotherapies and counsel that immune phenotype is a crucial metric for eliciting therapeutic anti-cytokine antibody responses.

antibodysource
NANOG Peptide |
|||
MBS3233776-01mg | MyBiosource | 0.1mg | 180 EUR |
NANOG Peptide |
|||
MBS3233776-5x01mg | MyBiosource | 5x0.1mg | 730 EUR |
NANOG Peptide - middle region |
|||
MBS3225197-01mg | MyBiosource | 0.1mg | 180 EUR |
NANOG Peptide - middle region |
|||
MBS3225197-5x01mg | MyBiosource | 5x0.1mg | 730 EUR |
NANOG Peptide - middle region |
|||
MBS3248655-01mg | MyBiosource | 0.1mg | 180 EUR |
NANOG Peptide - middle region |
|||
MBS3248655-5x01mg | MyBiosource | 5x0.1mg | 730 EUR |
Nanog Blocking Peptide |
|||
33R-2746 | Fitzgerald | 100 ug | 119 EUR |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of NANOG antibody, catalog no. 70R-3067 |
|||
NANOG Blocking Peptide |
|||
BF0323-BP | Affbiotech | 1mg | 234 EUR |
Nanog Blocking Peptide |
|||
AF5388-BP | Affbiotech | 1mg | 234 EUR |
Nanog Blocking Peptide |
|||
AF4011-BP | Affbiotech | 1mg | 234 EUR |
Nanog Blocking Peptide |
|||
MBS9617092-1mg | MyBiosource | 1mg | 380 EUR |
Nanog Blocking Peptide |
|||
MBS9617092-5x1mg | MyBiosource | 5x1mg | 1650 EUR |
Nanog Blocking Peptide |
|||
MBS9617637-1mg | MyBiosource | 1mg | 380 EUR |
Nanog Blocking Peptide |
|||
MBS9617637-5x1mg | MyBiosource | 5x1mg | 1650 EUR |
NANOG Blocking Peptide |
|||
MBS9620010-1mg | MyBiosource | 1mg | 380 EUR |
NANOG Blocking Peptide |
|||
MBS9620010-5x1mg | MyBiosource | 5x1mg | 1650 EUR |
Nanog Blocking Peptide |
|||
MBS9616338-1mg | MyBiosource | 1mg | 380 EUR |
Nanog Blocking Peptide |
|||
MBS9616338-5x1mg | MyBiosource | 5x1mg | 1650 EUR |
NANOG Blocking Peptide |
|||
MBS8309049-1mg | MyBiosource | 1mg | 190 EUR |
NANOG Blocking Peptide |
|||
MBS8309049-5mg | MyBiosource | 5mg | 345 EUR |
NANOG Blocking Peptide |
|||
MBS8309049-5x5mg | MyBiosource | 5x5mg | 1465 EUR |
AAP47988-100UG - NANOG Peptide |
|||
AAP47988-100UG | Aviva Systems Biology | 100ug | 99 EUR |
NANOG Immunizing Peptide |
|||
MBS428110-01mg | MyBiosource | 0.1mg | 225 EUR |
Nanog Immunizing Peptide |
|||
MBS428233-01mg | MyBiosource | 0.1mg | 225 EUR |
NANOG Immunizing Peptide |
|||
MBS426162-01mg | MyBiosource | 0.1mg | 225 EUR |
Nanog P8 Blocking Peptide |
|||
AF9122-BP | Affbiotech | 1mg | 234 EUR |
Nanog P8 Blocking Peptide |
|||
MBS9619619-1mg | MyBiosource | 1mg | 380 EUR |
Nanog P8 Blocking Peptide |
|||
MBS9619619-5x1mg | MyBiosource | 5x1mg | 1650 EUR |
NANOG Peptide - N-terminal region |
|||
MBS3225249-01mg | MyBiosource | 0.1mg | 180 EUR |
NANOG Peptide - N-terminal region |
|||
MBS3225249-5x01mg | MyBiosource | 5x0.1mg | 730 EUR |
NANOG Blocking Peptide (Center) |
|||
MBS9229947-INQUIRE | MyBiosource | INQUIRE | Ask for price |
AAP30891-100UG - NANOG Peptide - middle region |
|||
AAP30891-100UG | Aviva Systems Biology | 100ug | 99 EUR |
NANOG Antibody (S285) Blocking Peptide |
|||
MBS9221186-INQUIRE | MyBiosource | INQUIRE | Ask for price |
NANOG Antibody (Center) Blocking Peptide |
|||
MBS9221185-INQUIRE | MyBiosource | INQUIRE | Ask for price |
NANOG Antibody (N-term) Blocking Peptide |
|||
MBS9221184-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Mast Cell-Degranulating Peptide (MCD Peptide) / Peptide 401 |
|||
004-04 | PHOENIX PEPTIDE | 100 μg | 140.4 EUR |
Peptide T |
|||
057-01 | PHOENIX PEPTIDE | 5 mg | 140.4 EUR |
FGL Peptide |
|||
073-36 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
APK peptide |
|||
076-81 | PHOENIX PEPTIDE | 200 μg | 199.8 EUR |
NEF peptide |
|||
076-83 | PHOENIX PEPTIDE | 500 μg | 140.4 EUR |
SHA peptide |
|||
076-84 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
YSY peptide |
|||
076-86 | PHOENIX PEPTIDE | 100 μg | 230.04 EUR |
Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine) |
|||
024-57 | PHOENIX PEPTIDE | 200 μg | 86.4 EUR |
PSTAIR Peptide |
|||
070-61 | PHOENIX PEPTIDE | 500 μg | 129.6 EUR |
PGMtide Peptide |
|||
040-69 | PHOENIX PEPTIDE | 100 μg | 316.44 EUR |
Adjuvant Peptide |
|||
070-05 | PHOENIX PEPTIDE | 500 μg | 36.72 EUR |
Peptide-epsilon |
|||
058-22 | PHOENIX PEPTIDE | 500 μg | 114.48 EUR |
Delicious Peptide |
|||
070-21 | PHOENIX PEPTIDE | 5 mg | 160.92 EUR |
proSex peptide (20-55) |
|||
040-30 | PHOENIX PEPTIDE | 100 μg | 355.32 EUR |
proSex peptide (28-55) |
|||
040-31 | PHOENIX PEPTIDE | 100 μg | 282.96 EUR |
proSex peptide (40-55) |
|||
040-32 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
007-60 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
Peptide F-9 |
|||
038-06 | PHOENIX PEPTIDE | 200 μg | 58.32 EUR |
Sturgeon Peptide (137-158) |
|||
021-94 | PHOENIX PEPTIDE | 100 μg | 177.12 EUR |
Peptide Lv (Rat) |
|||
008-73 | PHOENIX PEPTIDE | 100 μg | 469.8 EUR |
NGR Peptide 1 |
|||
025-74 | PHOENIX PEPTIDE | 200 μg | 184.68 EUR |
Anorexigenic Peptide |
|||
070-10 | PHOENIX PEPTIDE | 5 mg | 86.4 EUR |
GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
029-03 | PHOENIX PEPTIDE | 500 μg | 114.48 EUR |
GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
029-04 | PHOENIX PEPTIDE | 100 μg | 114.48 EUR |
GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
029-05 | PHOENIX PEPTIDE | 20 μg | 267.84 EUR |
GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
029-06 | PHOENIX PEPTIDE | 100 μg | 114.48 EUR |
Bid BH3 peptide |
|||
025-87 | PHOENIX PEPTIDE | 1 mg | 170.64 EUR |
AF-16 Peptide |
|||
033-44 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Peptide Lv (Human) |
|||
008-71 | PHOENIX PEPTIDE | 100 μg | 405 EUR |
Peptide Lv (Mouse) |
|||
008-72 | PHOENIX PEPTIDE | 100 μg | 469.8 EUR |
GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat) |
|||
029-08 | PHOENIX PEPTIDE | 200 μg | 64.8 EUR |
ExE peptide M3mP6 |
|||
064-33 | PHOENIX PEPTIDE | 200 μg | 244.08 EUR |
Peptide B (Bovine) |
|||
024-56 | PHOENIX PEPTIDE | 200 μg | 81 EUR |
Peptide F (Bovine) |
|||
024-58 | PHOENIX PEPTIDE | 200 μg | 114.48 EUR |
PLP Peptide (103-116) (Bovine) |
|||
070-14 | PHOENIX PEPTIDE | 5 mg | 140.4 EUR |
FMRF-Like Peptide |
|||
047-32 | PHOENIX PEPTIDE | 1 mg | 27 EUR |
Joining Peptide (Rat) |
|||
047-91 | PHOENIX PEPTIDE | 200 μg | 160.92 EUR |
Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog) |
|||
048-80 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog) |
|||
048-81 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog) |
|||
048-82 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Peptide T (4-8) |
|||
057-04 | PHOENIX PEPTIDE | 500 μg | 64.8 EUR |
Peptide T (5-8) |
|||
057-05 | PHOENIX PEPTIDE | 500 μg | 64.8 EUR |
Vasonatrin Peptide (VNP) |
|||
005-47 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Opioid Peptide Library |
|||
L-002 | PHOENIX PEPTIDE | 58 peptides | 2691.36 EUR |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) |
|||
064-01 | PHOENIX PEPTIDE | 200 μg | 108 EUR |
PGMtide Control Peptide |
|||
040-70 | PHOENIX PEPTIDE | 100 μg | 316.44 EUR |
Growth Blocking Peptide |
|||
046-92 | PHOENIX PEPTIDE | 100 μg | 255.96 EUR |
Neuron Specific Peptide |
|||
047-55 | PHOENIX PEPTIDE | 200 μg | 140.4 EUR |
Heparin Binding Peptide |
|||
025-47 | PHOENIX PEPTIDE | 500 μg | 102.6 EUR |
Gastrin Related Peptide |
|||
027-09 | PHOENIX PEPTIDE | 5 mg | 73.44 EUR |
Obesity Peptide Library |
|||
L-003 | PHOENIX PEPTIDE | 160 peptides | 7267.32 EUR |
[D-Ala1]-Peptide T |
|||
057-02 | PHOENIX PEPTIDE | 5 mg | 282.96 EUR |
Peptide YY (PYY) (Human) |
|||
059-01 | PHOENIX PEPTIDE | 200 μg | 119.88 EUR |
Eledoisin Related Peptide |
|||
046-04 | PHOENIX PEPTIDE | 5 mg | 58.32 EUR |
proSex peptide (28-55) - EIA Kit |
|||
EK-040-31 | PHOENIX PEPTIDE | 96 wells | 603.72 EUR |
Peptide F 1 (Lobster) |
|||
047-62 | PHOENIX PEPTIDE | 500 μg | 73.44 EUR |
Morphine Tolerance Peptide |
|||
050-13 | PHOENIX PEPTIDE | 1 mg | 102.6 EUR |
Phosphate Acceptor Peptide |
|||
058-24 | PHOENIX PEPTIDE | 500 μg | 73.44 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) |
|||
064-07 | PHOENIX PEPTIDE | 200 μg | 114.48 EUR |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia brasiliana) |
|||
047-39 | PHOENIX PEPTIDE | 200 μg | 444.96 EUR |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia brasiliana) |
|||
047-40 | PHOENIX PEPTIDE | 500 μg | 214.92 EUR |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia californica) |
|||
047-42 | PHOENIX PEPTIDE | 200 μg | 444.96 EUR |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia californica) |
|||
047-43 | PHOENIX PEPTIDE | 500 μg | 214.92 EUR |
FGL Peptide - FAM Labeled |
|||
FG-073-36A | PHOENIX PEPTIDE | 1 nmol | 405 EUR |
FGL Peptide - Cy3 Labeled |
|||
FC3-073-36 | PHOENIX PEPTIDE | 1 nmol | 672.84 EUR |
FGL Peptide - Cy5 Labeled |
|||
FC5-073-36 | PHOENIX PEPTIDE | 1 nmol | 756 EUR |
Pedal Peptide (Pep) (Aplysia) |
|||
047-61 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
ExE peptide M3mP6 mutant |
|||
064-35 | PHOENIX PEPTIDE | 200ug | 234.36 EUR |
ExE peptide M3mP6 mutant |
|||
064-37 | PHOENIX PEPTIDE | 200ug | 234.36 EUR |
FGL Peptide - FITC Labeled |
|||
FG-073-36B | PHOENIX PEPTIDE | 1 nmol | 405 EUR |
AF-16 Peptide - Antibody |
|||
H-033-44 | PHOENIX PEPTIDE | 100 μl | 336.96 EUR |
Schizophrenia Related Peptide |
|||
047-79 | PHOENIX PEPTIDE | 5 mg | 44.28 EUR |
Insulin B (22-25) Peptide |
|||
035-08 | PHOENIX PEPTIDE | 5 mg | 86.4 EUR |
Eosinophilotactic Peptide (AGSE) |
|||
070-28 | PHOENIX PEPTIDE | 5 mg | 27 EUR |
Eosinophilotactic Peptide (VGSE) |
|||
070-29 | PHOENIX PEPTIDE | 5 mg | 27 EUR |
Cell Penetrating ARF Peptide (26-44) |
|||
068-56 | PHOENIX PEPTIDE | 500 μg | 640.44 EUR |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - RIA Kit |
|||
RK-064-01 | PHOENIX PEPTIDE | 125 tubes | 932.04 EUR |
FGL Peptide - Biotin Labeled |
|||
B-073-36 | PHOENIX PEPTIDE | 20 μg | 405 EUR |
Peptide F (Bovine) - Antibody |
|||
H-024-58 | PHOENIX PEPTIDE | 50 μl | 238.68 EUR |
Brain Peptide (Bees) Library |
|||
L-007 | PHOENIX PEPTIDE | 51 peptides | 6456.24 EUR |
Gastrointestinal Peptide Library |
|||
L-006 | PHOENIX PEPTIDE | 200 peptides | 7267.32 EUR |
Peptide R / CXCR4 Antagonist |
|||
030-25 | PHOENIX PEPTIDE | 200 μg | 203.04 EUR |
PGMtide Peptide - FAM Labeled |
|||
FG-040-69A | PHOENIX PEPTIDE | 5 nmol | 537.84 EUR |
PGMtide Peptide - Cy3 Labeled |
|||
FC3-040-69 | PHOENIX PEPTIDE | 1 nmol | 925.56 EUR |
[D-Arg14, D-Arg15]-MGF Peptide amide / C-terminal peptide of IGF-1 Ec amide |
|||
033-34 | PHOENIX PEPTIDE | 100 μg | 177.12 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Antibody |
|||
H-064-07 | PHOENIX PEPTIDE | 50 μl | 238.68 EUR |
[D-Ala1]-Peptide T amide |
|||
057-03 | PHOENIX PEPTIDE | 500 μg | 140.4 EUR |
Peptide F (Bovine) - RIA Kit |
|||
RK-024-58 | PHOENIX PEPTIDE | 125 tubes | 932.04 EUR |
Calmodulin Binding Peptide 1 |
|||
070-17 | PHOENIX PEPTIDE | 20 μg | 214.92 EUR |
Catch-Relaxing Peptide (CARP) |
|||
047-20 | PHOENIX PEPTIDE | 1 mg | 199.8 EUR |
FGL Peptide - Rhodamine Labeled |
|||
FR-073-36 | PHOENIX PEPTIDE | 1 nmol | 537.84 EUR |
Peptide-Depleted Plasma (Rat) |
|||
MB-099-02 | PHOENIX PEPTIDE | 2 ml | 119.88 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit |
|||
RK-064-07 | PHOENIX PEPTIDE | 125 tubes | 932.04 EUR |
Glycogenolysis-Inhibiting Peptide |
|||
023-63 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
Anti-Inflammatory Peptide 1 |
|||
004-01 | PHOENIX PEPTIDE | 200 μg | 27 EUR |
Anti-Inflammatory Peptide 2 |
|||
004-02 | PHOENIX PEPTIDE | 200 μg | 27 EUR |
Anti-Inflammatory Peptide 3 |
|||
004-03 | PHOENIX PEPTIDE | 200 μg | 27 EUR |
Urokinase-Derived Peptide A6 |
|||
025-12 | PHOENIX PEPTIDE | 500 μg | 129.6 EUR |
PGMtide Peptide - Biotin Labeled |
|||
B-040-69 | PHOENIX PEPTIDE | 20 μg | 537.84 EUR |
Peptide 34 / GPR-54 Agonist |
|||
048-94 | PHOENIX PEPTIDE | 200 μg | 114.48 EUR |
FGL Peptide - I-125 Labeled |
|||
T-073-36 | PHOENIX PEPTIDE | 10 μCi | 1145.88 EUR |
Peptide-Depleted Plasma (Human) |
|||
MB-099-01 | PHOENIX PEPTIDE | 2 ml | 119.88 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled |
|||
FG-064-07A | PHOENIX PEPTIDE | 1 nmol | 336.96 EUR |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - I-125 Labeled |
|||
T-064-01 | PHOENIX PEPTIDE | 10 μCi | 1145.88 EUR |
F3 Peptide / HMGN2 Fragment 3 |
|||
004-12 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
Antimicrobial Trp-rich peptide |
|||
004-05 | PHOENIX PEPTIDE | 100 μg | 140.4 EUR |
Myosin Kinase Inhibiting Peptide |
|||
058-20 | PHOENIX PEPTIDE | 500 μg | 50.76 EUR |
Fibronectin CS1 Peptide (EILDVPST) |
|||
025-20 | PHOENIX PEPTIDE | 500 μg | 86.4 EUR |
Peptide YY (PYY) (3-36) (Human) |
|||
059-02 | PHOENIX PEPTIDE | 200 μg | 102.6 EUR |
Peptide YY (PYY) (Human) - Antibody |
|||
H-059-01 | PHOENIX PEPTIDE | 100 μl | 469.8 EUR |
PGMtide Peptide - Rhodamine Labeled |
|||
FR-040-69 | PHOENIX PEPTIDE | 5 nmol | 604.8 EUR |
Anti-Angiogenic Peptide Library |
|||
L-008A | PHOENIX PEPTIDE | 88 peptides | 6067.44 EUR |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - Purified IgG Antibody |
|||
G-064-01 | PHOENIX PEPTIDE | 400 μg | 438.48 EUR |
Peptide A / p60v-src (137-157) |
|||
058-21 | PHOENIX PEPTIDE | 500 μg | 135 EUR |
pro-Opionmelanocortin / J Peptide |
|||
022-22 | PHOENIX PEPTIDE | 200 μg | 177.12 EUR |
Cancer-Targeting Peptide Library |
|||
L-015 | PHOENIX PEPTIDE | 289 peptides | 7253.28 EUR |
C28 optimized peptide 6 (Human) |
|||
073-82 | PHOENIX PEPTIDE | 100 μg | 235.44 EUR |
Peptide YY (PYY) (Human) - EIA Kit |
|||
EK-059-01 | PHOENIX PEPTIDE | 96 wells | 617.76 EUR |
Peptide YY (PYY) (Human) - RIA Kit |
|||
RK-059-01 | PHOENIX PEPTIDE | 125 tubes | 814.32 EUR |
Kemptide / Phosphate Acceptor Peptide |
|||
058-16 | PHOENIX PEPTIDE | 500 μg | 36.72 EUR |
Bioactive Secretory Peptide Library |
|||
L-009 | PHOENIX PEPTIDE | 1016 peptides | 31350.24 EUR |
PACAP-Related Peptide (PRP) (Rat) |
|||
052-11 | PHOENIX PEPTIDE | 200 μg | 86.4 EUR |
Galanin-Like Peptide (GALP) (Rat) |
|||
026-52 | PHOENIX PEPTIDE | 100 μg | 282.96 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - I-125 Labeled |
|||
T-064-07 | PHOENIX PEPTIDE | 10 μCi | 1145.88 EUR |
Virus Replication Inhibiting Peptide |
|||
070-85 | PHOENIX PEPTIDE | 5 mg | 160.92 EUR |
Prognostic Affect of B-Kind Natriuretic Peptide on Lengthy-Time period Medical Outcomes in Sufferers with Non-ST-Section Elevation Acute Myocardial Infarction With out Creatine Kinase Elevation
Though B-type natriuretic peptide (BNP) has regularly gained recognition as an indicator in danger stratification for sufferers with acute myocardial infarction (AMI), the prognostic affect on long-term medical outcomes in sufferers with non-ST-segment elevation acute myocardial infarction (NSTEMI) with out creatine kinase (CK) elevation stays unclear.This potential multicenter research assessed 3,283 consecutive sufferers with AMI admitted to 28 establishments in Japan between 2012 and 2014.
We analyzed 218 sufferers with NSTEMI with out CK elevation (NSTEMI-CK) for whom BNP was obtainable. Within the NSTEMI-CK group, sufferers had been assigned to high- and low-BNP teams in line with BNP values (cut-off BNP, 100 pg/mL). The main endpoint was outlined as a composite of all-cause demise, non-fatal myocardial infarction, non-fatal stroke, cardiac failure, and pressing revascularization for unstable angina as much as Three years.
Main endpoints had been noticed in 60 (33.3%) occasions amongst sufferers with NSTEMI-CK. Kaplan-Meier evaluation revealed a considerably increased occasion charge for main endpoints amongst sufferers with excessive BNP (log-rank P < 0.001). After adjusting for covariates, the next BNP stage was considerably related with long-term medical outcomes in NSTEMI-CK (adjusted hazard ratio, 4.86; 95% confidence interval, 2.18-12.44; P < 0.001).The BNP focus is related to adversarial long-term medical outcomes amongst sufferers with NSTEMI-CK who’re thought of low danger. Cautious medical administration could also be warranted for secondary prevention in sufferers with NSTEMI-CK with excessive BNP ranges.
Towards the Discovery of Host-Protection Peptides in Crops
Protection peptides defend multicellular eukaryotes from infections. In biomedical sciences, a dominant conceptual framework refers to protection peptides as host-defense peptides (HDPs), that are bifunctional peptides with each direct antimicrobial and immunomodulatory actions.
No HDP has been reported in vegetation to date, and the very idea of HDP has not been captured but by the plant science neighborhood. Plant science thus lacks the conceptual framework that might coordinate analysis efforts aimed toward discovering plant HDPs.
On this perspective article, I used bibliometric and literature survey approaches to lift consciousness concerning the HDP idea amongst plant scientists, and to encourage analysis efforts aimed toward discovering plant HDPs. Such discovery would enrich our comprehension of the operate and evolution of the plant immune system, and supply us with novel molecular instruments to develop progressive methods to manage crop ailments.
Cruzioseptins, antibacterial peptides from Cruziohyla calcarifer pores and skin, as promising leishmanicidal brokers
Screenings of pure merchandise have considerably contributed to the invention of novel leishmanicidal brokers. On this research, three identified cruzioseptins-antibacterial peptides from Cruziohyla calcarifer skin-were synthesized and evaluated in opposition to promastigotes and amastigotes levels of Leishmania (L.) amazonensis and L. (V.) braziliensis. EC50 ranged from 9.17 µM to 74.82 µM, being cruzioseptin-1 probably the most energetic and selective compound, with selectivity index > 10 for each promastigotes and amastigotes of L. (V.) braziliensis.
In vitro infections incubated with cruzioseptins at 50 µM confirmed as much as ∼86% discount within the amastigote quantity. Cruzioseptins had been capable of destabilize the parasite’s cell membrane, permitting the incorporation of a DNA-fluorescent dye. Our information additionally demonstrated that hydrophobicity and cost look like advantageous options for enhancing parasiticidal exercise. Antimicrobial cruzioseptins are appropriate candidates and different molecules that deserve additional in vivo investigation specializing in the event of novel antileishmanial therapies.
CTRP2 Peptide |
|||
3561P | ProSci | 0.05 mg | 197.7 EUR |
Description: (NT) CTRP2 peptide |
|||
CTRP3 Peptide |
|||
3565P | ProSci | 0.05 mg | 197.7 EUR |
Description: (IN) CTRP3 peptide |
|||
CTRP4 Peptide |
|||
3567P | ProSci | 0.05 mg | 197.7 EUR |
Description: (CT) CTRP4 peptide |
|||
CTRP4 Peptide |
|||
3569P | ProSci | 0.05 mg | 197.7 EUR |
Description: (IN) CTRP4 peptide |
|||
CTRP5 Peptide |
|||
3571P | ProSci | 0.05 mg | 197.7 EUR |
Description: (NT) CTRP5 peptide |
|||
CTRP5 Peptide |
|||
3573P | ProSci | 0.05 mg | 197.7 EUR |
Description: (IN) CTRP5 peptide |
|||
CTRP6 Peptide |
|||
3575P | ProSci | 0.05 mg | 197.7 EUR |
Description: (CT) CTRP6 peptide |
|||
CTRP6 Peptide |
|||
3577P | ProSci | 0.05 mg | 197.7 EUR |
Description: (IN) CTRP6 peptide |
|||
CTRP6 Peptide |
|||
MBS151976-005mg | MyBiosource | 0.05mg | 175 EUR |
CTRP6 Peptide |
|||
MBS151976-5x005mg | MyBiosource | 5x0.05mg | 770 EUR |
CTRP1 Peptide |
|||
MBS152035-005mg | MyBiosource | 0.05mg | 175 EUR |
CTRP1 Peptide |
|||
MBS152035-5x005mg | MyBiosource | 5x0.05mg | 770 EUR |
CTRP5 Peptide |
|||
MBS152063-005mg | MyBiosource | 0.05mg | 175 EUR |
CTRP5 Peptide |
|||
MBS152063-5x005mg | MyBiosource | 5x0.05mg | 770 EUR |
CTRP6 Peptide |
|||
MBS152087-005mg | MyBiosource | 0.05mg | 175 EUR |
CTRP6 Peptide |
|||
MBS152087-5x005mg | MyBiosource | 5x0.05mg | 770 EUR |
CTRP5 Peptide |
|||
MBS152140-005mg | MyBiosource | 0.05mg | 175 EUR |
CTRP5 Peptide |
|||
MBS152140-5x005mg | MyBiosource | 5x0.05mg | 770 EUR |
CTRP4 Peptide |
|||
MBS152271-005mg | MyBiosource | 0.05mg | 175 EUR |
CTRP4 Peptide |
|||
MBS152271-5x005mg | MyBiosource | 5x0.05mg | 770 EUR |
CTRP2 Peptide |
|||
MBS152414-005mg | MyBiosource | 0.05mg | 175 EUR |
CTRP2 Peptide |
|||
MBS152414-5x005mg | MyBiosource | 5x0.05mg | 770 EUR |
CTRP3 Peptide |
|||
MBS152457-005mg | MyBiosource | 0.05mg | 175 EUR |
CTRP3 Peptide |
|||
MBS152457-5x005mg | MyBiosource | 5x0.05mg | 770 EUR |
CTRP4 Peptide |
|||
MBS152506-005mg | MyBiosource | 0.05mg | 175 EUR |
CTRP4 Peptide |
|||
MBS152506-5x005mg | MyBiosource | 5x0.05mg | 770 EUR |
CTRP1 Peptide |
|||
MBS152726-005mg | MyBiosource | 0.05mg | 175 EUR |
CTRP1 Peptide |
|||
MBS152726-5x005mg | MyBiosource | 5x0.05mg | 770 EUR |
CTRP2 Peptide |
|||
MBS152939-005mg | MyBiosource | 0.05mg | 175 EUR |
CTRP2 Peptide |
|||
MBS152939-5x005mg | MyBiosource | 5x0.05mg | 770 EUR |
Peptide T |
|||
057-01 | PHOENIX PEPTIDE | 5 mg | 140.4 EUR |
FGL Peptide |
|||
073-36 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
APK peptide |
|||
076-81 | PHOENIX PEPTIDE | 200 μg | 199.8 EUR |
NEF peptide |
|||
076-83 | PHOENIX PEPTIDE | 500 μg | 140.4 EUR |
SHA peptide |
|||
076-84 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
YSY peptide |
|||
076-86 | PHOENIX PEPTIDE | 100 μg | 230.04 EUR |
Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine) |
|||
024-57 | PHOENIX PEPTIDE | 200 μg | 86.4 EUR |
PSTAIR Peptide |
|||
070-61 | PHOENIX PEPTIDE | 500 μg | 129.6 EUR |
PGMtide Peptide |
|||
040-69 | PHOENIX PEPTIDE | 100 μg | 316.44 EUR |
Adjuvant Peptide |
|||
070-05 | PHOENIX PEPTIDE | 500 μg | 36.72 EUR |
Peptide-epsilon |
|||
058-22 | PHOENIX PEPTIDE | 500 μg | 114.48 EUR |
Delicious Peptide |
|||
070-21 | PHOENIX PEPTIDE | 5 mg | 160.92 EUR |
proSex peptide (20-55) |
|||
040-30 | PHOENIX PEPTIDE | 100 μg | 355.32 EUR |
proSex peptide (28-55) |
|||
040-31 | PHOENIX PEPTIDE | 100 μg | 282.96 EUR |
proSex peptide (40-55) |
|||
040-32 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
007-60 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
Peptide F-9 |
|||
038-06 | PHOENIX PEPTIDE | 200 μg | 58.32 EUR |
Sturgeon Peptide (137-158) |
|||
021-94 | PHOENIX PEPTIDE | 100 μg | 177.12 EUR |
P59-Amide / CTRP8 (100-121)-Amide (Human) |
|||
036-40 | PHOENIX PEPTIDE | 100 μg | 244.08 EUR |
NGR Peptide 1 |
|||
025-74 | PHOENIX PEPTIDE | 200 μg | 184.68 EUR |
Peptide Lv (Rat) |
|||
008-73 | PHOENIX PEPTIDE | 100 μg | 469.8 EUR |
Anorexigenic Peptide |
|||
070-10 | PHOENIX PEPTIDE | 5 mg | 86.4 EUR |
GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
029-03 | PHOENIX PEPTIDE | 500 μg | 114.48 EUR |
GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
029-04 | PHOENIX PEPTIDE | 100 μg | 114.48 EUR |
GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
029-05 | PHOENIX PEPTIDE | 20 μg | 267.84 EUR |
GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
029-06 | PHOENIX PEPTIDE | 100 μg | 114.48 EUR |
Anti - CTRP7 |
|||
MBS684121-002mL | MyBiosource | 0.02mL | 270 EUR |
Anti - CTRP7 |
|||
MBS684121-005mL | MyBiosource | 0.05mL | 405 EUR |
Anti - CTRP7 |
|||
MBS684121-01mL | MyBiosource | 0.1mL | 585 EUR |
Bid BH3 peptide |
|||
025-87 | PHOENIX PEPTIDE | 1 mg | 170.64 EUR |
AF-16 Peptide |
|||
033-44 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
CTRP3 Blocking Peptide |
|||
MBS9622335-1mg | MyBiosource | 1mg | 380 EUR |
CTRP3 Blocking Peptide |
|||
MBS9622335-5x1mg | MyBiosource | 5x1mg | 1650 EUR |
Peptide Lv (Human) |
|||
008-71 | PHOENIX PEPTIDE | 100 μg | 405 EUR |
Peptide Lv (Mouse) |
|||
008-72 | PHOENIX PEPTIDE | 100 μg | 469.8 EUR |
GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat) |
|||
029-08 | PHOENIX PEPTIDE | 200 μg | 64.8 EUR |
ExE peptide M3mP6 |
|||
064-33 | PHOENIX PEPTIDE | 200 μg | 244.08 EUR |
Peptide B (Bovine) |
|||
024-56 | PHOENIX PEPTIDE | 200 μg | 81 EUR |
Peptide F (Bovine) |
|||
024-58 | PHOENIX PEPTIDE | 200 μg | 114.48 EUR |
PLP Peptide (103-116) (Bovine) |
|||
070-14 | PHOENIX PEPTIDE | 5 mg | 140.4 EUR |
FMRF-Like Peptide |
|||
047-32 | PHOENIX PEPTIDE | 1 mg | 27 EUR |
Joining Peptide (Rat) |
|||
047-91 | PHOENIX PEPTIDE | 200 μg | 160.92 EUR |
Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog) |
|||
048-80 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog) |
|||
048-81 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog) |
|||
048-82 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
CTRP7 Antibody |
|||
3579-002mg | ProSci | 0.02 mg | 206.18 EUR |
Description: CTRP7 Antibody: Adipose tissue of an organism plays a major role in regulating physiologic and pathologic processes such as metabolism and immunity by producing and secreting a variety of bioactive molecules termed adipokines. One highly conserved family of adipokines is adiponectin/ACRP30 and its structural and functional paralogs, the C1q/tumor necrosis factor-alpha-related proteins (CTRPs) 1-7. Unlike adiponectin, which is expressed exclusively by differentiated adipocytes, the CTRPs are expressed in a wide variety of tissues. These proteins are thought to act mainly on liver and muscle tissue to control glucose and lipid metabolism. An analysis of the crystal structure of adiponectin revealed a structural and evolutionary link between TNF and C1q-containing proteins, suggesting that these proteins arose from a common ancestral innate immunity gene. Like the other members of the adiponectin and CTRP protein family, the mature CTRP7 is secreted and can be found in the organism's circulatory system. |
|||
CTRP7 Antibody |
|||
3579-01mg | ProSci | 0.1 mg | 523.7 EUR |
Description: CTRP7 Antibody: Adipose tissue of an organism plays a major role in regulating physiologic and pathologic processes such as metabolism and immunity by producing and secreting a variety of bioactive molecules termed adipokines. One highly conserved family of adipokines is adiponectin/ACRP30 and its structural and functional paralogs, the C1q/tumor necrosis factor-alpha-related proteins (CTRPs) 1-7. Unlike adiponectin, which is expressed exclusively by differentiated adipocytes, the CTRPs are expressed in a wide variety of tissues. These proteins are thought to act mainly on liver and muscle tissue to control glucose and lipid metabolism. An analysis of the crystal structure of adiponectin revealed a structural and evolutionary link between TNF and C1q-containing proteins, suggesting that these proteins arose from a common ancestral innate immunity gene. Like the other members of the adiponectin and CTRP protein family, the mature CTRP7 is secreted and can be found in the organism's circulatory system. |
|||
CTRP7 Antibody |
|||
3581-002mg | ProSci | 0.02 mg | 206.18 EUR |
Description: CTRP7 Antibody: Adipose tissue of an organism plays a major role in regulating physiologic and pathologic processes such as metabolism and immunity by producing and secreting a variety of bioactive molecules termed adipokines. One highly conserved family of adipokines is adiponectin/ACRP30 and its structural and functional paralogs, the C1q/tumor necrosis factor-alpha-related proteins (CTRPs) 1-7. Unlike adiponectin, which is expressed exclusively by differentiated adipocytes, the CTRPs are expressed in a wide variety of tissues. These proteins are thought to act mainly on liver and muscle tissue to control glucose and lipid metabolism. An analysis of the crystal structure of adiponectin revealed a structural and evolutionary link between TNF and C1q-containing proteins, suggesting that these proteins arose from a common ancestral innate immunity gene. Like the other members of the adiponectin and CTRP protein family, the mature CTRP7 is secreted and can be found in the organism's circulatory system. |
|||
CTRP7 Antibody |
|||
3581-01mg | ProSci | 0.1 mg | 523.7 EUR |
Description: CTRP7 Antibody: Adipose tissue of an organism plays a major role in regulating physiologic and pathologic processes such as metabolism and immunity by producing and secreting a variety of bioactive molecules termed adipokines. One highly conserved family of adipokines is adiponectin/ACRP30 and its structural and functional paralogs, the C1q/tumor necrosis factor-alpha-related proteins (CTRPs) 1-7. Unlike adiponectin, which is expressed exclusively by differentiated adipocytes, the CTRPs are expressed in a wide variety of tissues. These proteins are thought to act mainly on liver and muscle tissue to control glucose and lipid metabolism. An analysis of the crystal structure of adiponectin revealed a structural and evolutionary link between TNF and C1q-containing proteins, suggesting that these proteins arose from a common ancestral innate immunity gene. Like the other members of the adiponectin and CTRP protein family, the mature CTRP7 is secreted and can be found in the organism's circulatory system. |
|||
CTRP7 Antibody |
|||
24336 | SAB | 100ul | 479 EUR |
CTRP7 Antibody |
|||
24336-100ul | SAB | 100ul | 468 EUR |
CTRP7 Antibody |
|||
24337 | SAB | 100ul | 479 EUR |
CTRP7 Antibody |
|||
24337-100ul | SAB | 100ul | 468 EUR |
CTRP7 Antibody |
|||
24378 | SAB | 100ul | 479 EUR |
CTRP7 Antibody |
|||
24378-100ul | SAB | 100ul | 468 EUR |
CTRP7 Antibody |
|||
3673-002mg | ProSci | 0.02 mg | 206.18 EUR |
Description: CTRP7 Antibody: Adipose tissue of an organism plays a major role in regulating physiologic and pathologic processes such as metabolism and immunity by producing and secreting a variety of bioactive molecules termed adipokines. One highly conserved family of adipokines is adiponectin/ACRP30 and its structural and functional paralogs, the C1q/tumor necrosis factor-alpha-related proteins (CTRPs) 1-7. Unlike adiponectin, which is expressed exclusively by differentiated adipocytes, the CTRPs are expressed in a wide variety of tissues. These proteins are thought to act mainly on liver and muscle tissue to control glucose and lipid metabolism. An analysis of the crystal structure of adiponectin revealed a structural and evolutionary link between TNF and C1q-containing proteins, suggesting that these proteins arose from a common ancestral innate immunity gene. Like the other members of the adiponectin and CTRP protein family, the mature CTRP7 is secreted and can be found in the organism's circulatory system. |
|||
CTRP7 Antibody |
|||
3673-01mg | ProSci | 0.1 mg | 523.7 EUR |
Description: CTRP7 Antibody: Adipose tissue of an organism plays a major role in regulating physiologic and pathologic processes such as metabolism and immunity by producing and secreting a variety of bioactive molecules termed adipokines. One highly conserved family of adipokines is adiponectin/ACRP30 and its structural and functional paralogs, the C1q/tumor necrosis factor-alpha-related proteins (CTRPs) 1-7. Unlike adiponectin, which is expressed exclusively by differentiated adipocytes, the CTRPs are expressed in a wide variety of tissues. These proteins are thought to act mainly on liver and muscle tissue to control glucose and lipid metabolism. An analysis of the crystal structure of adiponectin revealed a structural and evolutionary link between TNF and C1q-containing proteins, suggesting that these proteins arose from a common ancestral innate immunity gene. Like the other members of the adiponectin and CTRP protein family, the mature CTRP7 is secreted and can be found in the organism's circulatory system. |
|||
CTRP7 Antibody |
|||
MBS150140-01mg | MyBiosource | 0.1mg | 445 EUR |
CTRP7 Antibody |
|||
MBS150140-5x01mg | MyBiosource | 5x0.1mg | 1965 EUR |
CTRP7 Antibody |
|||
MBS150434-01mg | MyBiosource | 0.1mg | 445 EUR |